Odyssey Therapeutics, Inc. has set terms for its initial public offering, marketing 13.24 million shares at a price range of $16 to $18, implying a deal size of approximately $225 million at the midpoint. The company plans to list on the Nasdaq under the ticker ODTX, with J.P. Morgan, TD Cowen, and Cantor leading the offering alongside Wedbush, PacGrow, and Oppenheimer. Based on an assumed midpoint pricing, Odyssey would have an estimated post-offer market capitalization of roughly $760–$800 million (depending on final share count and concurrent private placement assumptions).
The deal is further supported by a $25 million concurrent private placement from TPG Orazio II, reinforcing institutional backing at the IPO price.
Odyssey is a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases, built around a differentiated approach targeting the innate immune system rather than downstream cytokines. The company’s strategy is rooted in the belief that existing therapies fail to adequately address disease biology due to cytokine redundancy and immunosuppressive side effects, leaving significant unmet need across conditions like inflammatory bowel disease (IBD) and lupus.
The platform combines deep immunology expertise with AI/ML-driven drug discovery, enabling rapid identification and optimization of both small molecules and protein therapeutics. Since its founding in 2021, Odyssey has built a diversified pipeline with multiple programs spanning discovery through clinical development.
At the center of the story is OD-001, an oral RIPK2 scaffolding inhibitor currently in Phase 2a for ulcerative colitis, which has already demonstrated proof-of-concept and favorable safety data. The drug targets a key signaling node in the innate immune system, with the potential to suppress multiple inflammatory cytokines simultaneously—positioning it as a potential step-change versus existing therapies that target individual pathways.
The company reported positive topline induction results in April 2026, showing patient benefit across disease-relevant endpoints with no serious adverse events, and plans to expand into both combination and monotherapy trials in the second half of 2026.
Behind OD-001 is a broader pipeline anchored by OD-002, an oral SLC15A4 inhibitor currently in IND-enabling studies targeting interferon-driven autoimmune diseases such as lupus. The program is expected to enter clinical trials in 2026, with additional preclinical assets spanning TNFR2 agonists, IRAK4 inhibitors, and bispecific inflammatory pathway blockers.
Financially, Odyssey reflects a typical high-growth biotech profile: the company generated minimal collaboration revenue and reported a net loss of $148.6 million in 2025, driven by heavy R&D investment across its expanding pipeline. As of March 2026, it held approximately $175.7 million in cash, which, combined with IPO proceeds, is expected to fund operations into the second half of 2028.
From a strategic standpoint, Odyssey is positioning itself as a next-generation immunology platform, emphasizing upstream pathway control, combination potential, and reduced immunosuppressive risk. The leadership team—led by CEO Gary Glick—brings a strong track record in biotech company creation and exits, including prior multi-billion-dollar transactions.
Odyssey enters a highly competitive immunology and biotech IPO landscape, where peers such as Nimbus Therapeutics, Kymera Therapeutics, and Scorpion Therapeutics (acquired by Eli Lilly) have highlighted investor appetite for platform-driven drug discovery companies. The key differentiator for Odyssey lies in its focus on innate immune signaling pathways, which could offer broader efficacy and improved combination strategies compared to cytokine-targeting incumbents. Valuation-wise, the deal appears in line with early-stage clinical biotech IPOs, particularly those with Phase 2 assets and platform optionality, though execution risk remains tied to clinical readouts over the next 12–24 months.
Odyssey Therapeutics is bringing a well-capitalized, platform-driven immunology story to market, anchored by early clinical validation in OD-001 and a deep pipeline behind it. While the company carries the typical risks of a clinical-stage biotech with no approved products, the combination of proof-of-concept data, institutional backing, and differentiated biology positions it as a notable entrant in the next wave of biotech IPOs.
Odyssey Therapeutics will makes its debut on Friday, May 8th.